Fortrea price target raised to $19 from $16 at Truist

Truist raised the firm’s price target on Fortrea (FTRE) to $19 from $16 and keeps a Buy rating on the shares. The firm is updating its model after holding talks with the company management to discuss Q1 results, 2026 guidance, and large pharma and biotech end-markets, the analyst tells investors in a research note. The company highlighted that near-term margin expansion is driven primarily by cost optimization, improved operational discipline, and reduced project overburn, with 2026 serving as a bridge year, the firm added.